Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-02-20, Stock:PFE, The news for the past five days is as follows:
2019-02-12: NEWS1: Bristol-Myers' Sprycel Gets European Nod for Label Expansion.NEWS2: Pfizer or Eli Lilly: Who Is Expected to Report Higher EPS Growth?.NEWS3: Pfizer or Eli Lilly: Who Will Report Better Revenue Growth?.NEWS4: What Analysts Recommend for Pfizer and Eli Lilly in February.NEWS5: Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review.NEWS6: Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review.NEWS7: Stock Market News For Feb 12, 2019.NEWS8: Stock Market News For Feb 12, 2019.NEWS9: Alnylam Pharmaceuticals Is Launched and Ready for More.NEWS10: Alnylam Pharmaceuticals Is Launched and Ready for More.NEWS11: Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review.NEWS12: Better Buy: Gilead Sciences vs. Pfizer.NEWS13: Better Buy: Gilead Sciences vs. Pfizer.NEWS14: Stock Market News For Feb 12, 2019.NEWS15: Health Care Sector Update for 02/12/2019: KMDA, GILD, MDGS, JNJ, PFE, MRK, ABT, AMGN.NEWS16: Health Care Sector Update for 02/12/2019: KMDA, GILD, MDGS, JNJ, PFE, MRK, ABT, AMGN.NEWS17: Better Buy: Gilead Sciences vs. Pfizer.NEWS18: Merck, Pfizer combo treatment boosts kidney cancer survival.
2019-02-13: NEWS1: Conatus (CNAT) Completes Enrollment in Phase II NASH Study.NEWS2: Conatus (CNAT) Completes Enrollment in Phase II NASH Study.NEWS3: Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4.NEWS4: Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4.NEWS5: Conatus (CNAT) Completes Enrollment in Phase II NASH Study.NEWS6: Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4.NEWS7: What Are the Key Growth Drivers for Pfizer in Fiscal 2019?.NEWS8: Health Care Sector Update for 02/13/2019: BABY, TEVA, EXEL, JNJ, PFE, ABT, MRK, AMGN.NEWS9: Health Care Sector Update for 02/13/2019: BABY, TEVA, EXEL, JNJ, PFE, ABT, MRK, AMGN.NEWS10: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for February 14, 2019.NEWS11: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for February 14, 2019.NEWS12: Allergan plc. (AGN) Ex-Dividend Date Scheduled for February 14, 2019.NEWS13: Allergan plc. (AGN) Ex-Dividend Date Scheduled for February 14, 2019.NEWS14: Pfizer and Eli Lilly: How Dividends and Tax Rates Stack Up.NEWS15: Pfizer or Eli Lilly: Who Is Controlling Expenses Better?.NEWS16: Dogs of the Dow and a 3 Top Dogs Strategy.NEWS17: Bristol-Myers' Sprycel Gets European Nod for Label Expansion.NEWS18: Bristol-Myers' Sprycel Gets European Nod for Label Expansion.
2019-02-14: NEWS1: Bayer stresses drug's tolerability in bid for prostate cancer market.NEWS2: The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial.NEWS3: Pfizer still holds the lead in the erectile dysfunction market even as Viagra sales falter.
2019-02-15: NEWS1: Pharmacia Corporation (Old Monsanto) -- Moody's announces completion of a periodic review of ratings of Pfizer Inc..NEWS2: This Is One Company That Could Break Up Bristol-Celgene Deal.NEWS3: Here&apos;s The Dark Horse Contender That Could Break Up Bristol-Celgene.NEWS4: Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review.NEWS5: Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review.NEWS6: What Are the Key Growth Drivers for GlaxoSmithKline in 2019?.NEWS7: Health Care Sector Update for 02/15/2019: AKAO, ORPN, CGC, JNJ, PFE, ABT, MRK, AMGN.NEWS8: Health Care Sector Update for 02/15/2019: AKAO, ORPN, CGC, JNJ, PFE, ABT, MRK, AMGN.NEWS9: Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review.NEWS10: See what the IHS Markit Score report has to say about Pfizer Inc..
2019-02-19: NEWS1: Spark Therapeutics (ONCE) Q4 2018 Earnings Conference Call Transcript.NEWS2: After Hours Most Active for Feb 19, 2019 :  SIRI, PFE, CHK, MO, VER, FDC, ZAYO, WBA, PYPL, AGNC, ADBE, SHY.NEWS3: After Hours Most Active for Feb 19, 2019 :  SIRI, PFE, CHK, MO, VER, FDC, ZAYO, WBA, PYPL, AGNC, ADBE, SHY.NEWS4: What's in Store for Sangamo (SGMO) This Earnings Season?.NEWS5: What's in Store for Sangamo (SGMO) This Earnings Season?.NEWS6: IWB, UNH, V, PFE: ETF Outflow Alert.NEWS7: IWB, UNH, V, PFE: ETF Outflow Alert.NEWS8: Ochsner Health System and Pfizer Partner to Develop Innovative Models for Clinical Trials.NEWS9: What's in Store for Sangamo (SGMO) This Earnings Season?.NEWS10: Health Care Sector Update for 02/19/2019: ICPT, MDT, NEO, JNJ, PFE, ABT, MRK, AMGN.NEWS11: Health Care Sector Update for 02/19/2019: ICPT, MDT, NEO, JNJ, PFE, ABT, MRK, AMGN.NEWS12: Pfizer Receives European Approval for ZIRABEV™ (bevacizumab), a Biosimilar to Avastin®*.NEWS13: Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster.NEWS14: Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster.NEWS15: Gliknik To Receive $15 Million Milestone Payment From Pfizer Inc. Following Clinical Progress With PF-06755347, Previously Known As GL-2045.NEWS16: Pfizer-Lilly drug shown to help reduce back pain in late-stage trial.NEWS17: Pfizer&apos;s Forgotten Cancer Pill Is About to Become Its Next Blockbuster.NEWS18: Higher dose of Pfizer-Lilly drug helps reduce back pain in study.NEWS19: Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain.

Answer: Decrease